



MAY 15 2006

PTO/SB/08B (8/03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO

COMPLETE IF KNOWN**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

10/801,519

Filing Date

03/16/2004

First Named Inventor

DONALD PINTO

Art Unit

1626

Examiner Name

FREISTEIN, ANDREW B

Attorney Docket Number

PH 7513 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
AF	AA	Bauer, K.A., "Fondaparinux: a new synthetic and selective inhibitor of Factor Xa", Best Practice & Research Clinical Haematology, Vol. 17, No. 1, pp. 89-104, 2004.	
AF	AB	Gresele et al., "Novel approaches to the treatment of thrombosis", TRENDS in Pharmacological Sciences, Vol. 23, No. 1, pp. 25-32, Jan 2002.	
AF	AC	Linkins et al., "New Anticoagulants", Seminars in Thrombosis and Hemostasis, Vol. 29, No. 6, pp. 619-631, 2003.	
AF	AD	Rauch et al., "Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences", Annals of Internal Medicine, Vol. 134, No. 3., pp. 224-238, 6 February 2001.	
AF	AE	Ruef et al., "New antithrombotic drugs on the horizon", Expert Opin. Investig. Drugs, Vol. 12, No. 5, pp. 781-797, 2003.	
AF	AF	Weitz et al., "Thrombophilia and New Anticoagulant Drugs", Hematology, pp. 424-438, 2004.	

Examiner
Signature

/Andrew Freistein/ (05/23/2006)

Date
Considered

05/23/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant